Effect of Fenofibrate on Lipid Levels of Type 2 Diabetic Patients With Dyslipidemia
Year: 2004
Type: article
Study design: Clinical Trial
Abstract: The effect of fenofibrate in type 2 diabetic patients with dyslipidemia was examined. Thirteen patients with type 2 diabetes mellitus and mixed hyperlipidemia; serum total cholesterol (TC)> 220 mg/dl and/or triglyceride (TG)> 150 mg/dl, were included in the study. Fenofibrate was administered at daily dose from 200 to 300 mg, and following items were implemented just prior to, at 3 months after, and at 6 months after the administration: amount of serum lipid, electrophoresis of lipoprotein by the method of polyacrylamide gel electrophoresis (PAGE), quantification of cholesterol (RLP-C) and triglyceride (RLP-TG) in remnant-like particle. TC significantly decreased at 6 months after administration (p<0.05), while TG at 3 and 6 months after administration was significantly lowered (p<0.05). Concentration of RLP-C that was 16.3 mg/dl before administration of fenofibrate decreased with statistical significance to attain 6.2 mg/dl and 7.2 mg/dl in 3 and 6 months after administration, respectively (p<O.Ol). In the case of RLP-TG, the concentration of 92.2 mg/dl before administration was observed to be lowered with time with statistical significance to reach 28.7 mg/dl and 32.7 mg/dl in 3 and 6 months, respectively (p<O.Ol). The low-density lipoprotein (LDL) particle size significantly increased at 6 months after administration (p<0.05). In all cases the remnant lipoprotein was observed on PAGE before administration, the bands disappeared or decreased in
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funder: Kaken Pharmaceutical
OpenAlex ID: W3193575681